A double-blind randomized placebo-controlled trial of topical tacrolimus 0.1% versus clobetasol propionate 0.05% in childhood vitiligo
British Journal of Dermatology, 04/04/2011
Clinical Article
Ho N et al. - Both clobetasol propionate 0.05% and tacrolimus 0.1% ointments offer similar benefit in both paediatric facial and non facial vitiligo. The facial lesions responded faster than the non-facial ones.
Methods- In this prospective study, children of 2-16 years of age with vitiligo, stratified into “facial”(n=55) and “non-facial”(n=45) groups.
- Randomized into three arms: CP 0.05% ointment (n =30), T 0.1% ointment (n=31) and placebo (n=29) for 6 months.
- Successful repigmentation, defined as > 50% improvement, was evaluated by comparing photographs taken at baseline and 2, 4, 6 months.
- In the facial group, 58.33% of the CP 0.05% group responded successfully compared with 57.78% of the T 0.1% group.
- In the non-facial group, 38.9% of the CP 0.05% group compared with 23% of the T 0.1% group (p= 0.3820).
- There was a significant difference in response between the CP 0.05% group vs placebo and the T 0.1% group vs placebo.
- Spontaneous repigmentation was evaluated as 2.4%. No significant clinical adverse events were noted in any group.
